Knight Therapeutics Inc. said its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA for NIKTIMVO (axatilimab) to treat chronic graft-versus-host disease after failure of at least two prior systemic therapies in adult and pediatric patients aged 6 and older. Knight stated it is responsible for seeking regulatory approvals and distributing axatilimab in Latin America under an amended agreement with Incyte, which will manufacture and supply the product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655931-en) on February 18, 2026, and is solely responsible for the information contained therein.